keyword
https://read.qxmd.com/read/38651330/exploring-therapeutic-targets-for-molecular-therapy-of-idiopathic-pulmonary-fibrosis
#21
REVIEW
Yue Li, Congshan Jiang, Wenhua Zhu, Shemin Lu, Hongchuan Yu, Liesu Meng
Idiopathic pulmonary fibrosis is a chronic and progressive interstitial lung disease with a poor prognosis. Idiopathic pulmonary fibrosis is characterized by repeated alveolar epithelial damage leading to abnormal repair. The intercellular microenvironment is disturbed, leading to continuous activation of fibroblasts and myofibroblasts, deposition of extracellular matrix, and ultimately fibrosis. Moreover, pulmonary fibrosis was also found as a COVID-19 complication. Currently, two drugs, pirfenidone and nintedanib, are approved for clinical therapy worldwide...
2024: Science Progress
https://read.qxmd.com/read/38651283/postmarket-safety-communications-on-drugs-approved-in-japan-a-25-year-analysis
#22
JOURNAL ARTICLE
Yusuke Tanaka, Mototsugu Tanaka, Haruna Miyazawa, Ryohei Terashima, Makoto Miyazawa, Mutsuhiro Ikuma, Yoshihiko Tomita
Drug safety communications (DSCs) are essential tools for communicating important postmarket serious drug safety information to healthcare professionals and patients. Previous studies characterized DSCs issued by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA); however, knowledge about the activities of the Pharmaceuticals and Medical Devices Agency (PMDA)/the Ministry of Health, Labor and Welfare (MHLW) is limited. This study characterized DSCs by the PMDA/MHLW in comparison with previously reported DSCs by the FDA and the EMA...
April 2024: Clinical and Translational Science
https://read.qxmd.com/read/38651245/comparative-pharmacokinetics-and-safety-assessment-of-1st-and-2nd-generation-zinpentraxin-alfa-drug-products-in-healthy-volunteers-a-randomized-crossover-study
#23
JOURNAL ARTICLE
Tu H Mai, Rajbharan Yadav, Audrey Arjomandi, Christine Jung, Monika M Meier, Francis Donaldson, Rui Zhao, Han-Ting Ding, Joy C Hsu, Nikhil Kamath, Lin Pan
Zinpentraxin alfa is a recombinant form of the human pentraxin-2 that was studied in idiopathic pulmonary fibrosis (IPF). To improve the purity and yield of the drug material, a 2nd-generation drug product was developed. To characterize and compare the pharmacokinetic (PK) properties of the 1st- and 2nd-generation zinpentraxin alfa, PK studies were conducted in healthy volunteers (HVs). In a phase 1 randomized, double-blind, 2-sequence crossover, sequential 2-stage study (ISRCTN59409907), single intravenous (IV) doses of 1st- and 2nd-generation zinpentraxin alfa at 10 mg/kg were studied with a blinded interim analysis (IA) at the end of stage 1...
April 23, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38651139/real-world-dalbavancin-use-for-serious-gram-positive-infections-comparing-outcomes-between-people-who-use-and-do-not-use-drugs
#24
JOURNAL ARTICLE
Sarah Zambrano, Molly L Paras, Joji Suzuki, Jeffrey C Pearson, Brandon Dionne, Harry Schrager, Jason Mallada, Veronica Szpak, Katie Fairbank-Haynes, Marlene Kalter, Sara Prostko, Daniel A Solomon
BACKGROUND: Dalbavancin has been used off-label to treat invasive bacterial infections in vulnerable populations like people who use drugs (PWUD) because of its broad gram-positive coverage and unique pharmacological properties. This retrospective, multisite study examined clinical outcomes at 90 days in PWUD versus non-PWUD after secondary treatment with dalbavancin for bacteremia, endocarditis, osteomyelitis, septic arthritis, and epidural abscesses. METHODS: Patients at 3 teaching hospitals who received dalbavancin for an invasive infection between March 2016 and May 2022 were included...
April 2024: Open Forum Infectious Diseases
https://read.qxmd.com/read/38651137/hepatitis-c-virus-antiviral-drug-resistance-and-salvage-therapy-outcomes-across-australia
#25
JOURNAL ARTICLE
Dao Sen Wang, Amy Phu, Kristen McKee, Simone I Strasser, Sinead Sheils, Martin Weltman, Sue Sellar, Joshua S Davis, Mel Young, Alicia Braund, Geoffrey C Farrell, Anne Blunn, Damian Harding, Lucy Ralton, Kate Muller, Scott A Davison, David Shaw, Marnie Wood, Krispin Hajkowicz, Richard Skolen, Jane Davies, Jaclyn Tate-Baker, Adam Doyle, Rhoda Tuma, Simon Hazeldine, Wendy Lam, Natalie Edmiston, Krista Zohrab, William Pratt, Belinda Watson, Amany Zekry, Carlie Stephens, Paul J Clark, Melany Day, Gordon Park, Hami Kim, Mark Wilson, Bruce McGarity, Natalie Menzies, Darren Russell, Thao Lam, Peter Boyd, Jen Kok, Jacob George, Mark W Douglas
BACKGROUND: Hepatitis C virus (HCV) infection can now be cured with well-tolerated direct-acting antiviral (DAA) therapy. However, a potential barrier to HCV elimination is the emergence of resistance-associated substitutions (RASs) that reduce the efficacy of antiviral drugs, but real-world studies assessing the clinical impact of RASs are limited. Here, an analysis of the impact of RASs on retreatment outcomes for different salvage regimens in patients nationally who failed first-line DAA therapy is reported...
April 2024: Open Forum Infectious Diseases
https://read.qxmd.com/read/38651072/downregulation-of-nat1-expression-is-associated-with-poor-prognosis-and-immune-infiltration-in-coad
#26
JOURNAL ARTICLE
Houxi Xu, Hongqun Zhang, Songxian Sun, Jingyuan Zhang, Jiege Huo, Chunxiang Zhou
BACKGROUND: An increasing corpus of evidence has identified the involvement of N-acetyltransferase 1 (NAT1), a member of the NAT family, in the progression of various cancers. However, the specific function of NAT1 in colon cancer (COAD) remains elusive. This study aims to decip her the role of NAT1 in COAD and its associated mechanisms. METHODS: The Tumor Immunity Evaluation Resource (TIMER), The Cancer Genome Atlas (TCGA), and the Gene Expression Omnibus (GEO) databases were employed to assess the NAT1 expression level in COAD...
2024: Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/38651061/bioinformatics-analysis-and-experimental-verification-of-tigd1-in-non-small-cell-lung-cancer
#27
JOURNAL ARTICLE
Lingchun Xia, Zhuofan Yang, Mingming Xv, Guohui Wang, Yaxin Mao, Yihan Yang, Jian Tang
INTRODUCTION: Non-small cell lung cancer (NSCLC) is a prevalent respiratory system tumor. Triggered transposable element derivative 1 (TIGD1) exhibits significant overexpression in various tumor cells and tissues, suggesting its involvement in cancer progression. METHODS: Clinical data and gene expression profiles of lung adenocarcinoma were collected from TCGA, UCSC XENA, and GEO databases. Computational techniques and empirical studies were employed to analyze the role of TIGD1 in NSCLC...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38650969/administration-and-effects-of-beta-blockers-and-oxandrolone-in-severely-burned-adults-a-post-hoc-analysis-of-the-re-energize-trial
#28
JOURNAL ARTICLE
Gabriel Hundeshagen, Elisabeth Blears, Viktoria Mertin, Andrew G Day, Alen Palackic, Christian Tapking, Valentin Haug, Ulrich Kneser, Björn Bliesener, Adriana C Panayi, Ariel Aballay, Francois Depret, Christian Stoppe, Daren K Heyland
BACKGROUND: Prospective randomized trials in severely burned children have shown the positive effects of oxandrolone (OX), beta blockers (BB) and a combination of the two (BBOX) on hypermetabolism, catabolism and hyperinflammation short- and long-term post-burn. Although data on severely burned adults are lacking in comparison, BB, OX and BBOX appear to be commonly employed in this patient population. In this study, we perform a secondary analysis of an international prospective randomized trial dataset to provide descriptive evidence regarding the current utilization patterns and potential treatment effects of OX, BB and BBOX...
2024: Burns and Trauma
https://read.qxmd.com/read/38650940/longitudinal-cytokine-and-multi-modal-health-data-of-an-extremely-severe-me-cfs-patient-with-hsd-reveals-insights-into-immunopathology-and-disease-severity
#29
JOURNAL ARTICLE
Fereshteh Jahanbani, Justin Cyril Sing, Rajan Douglas Maynard, Shaghayegh Jahanbani, Janet Dafoe, Whitney Dafoe, Nathan Jones, Kelvin J Wallace, Azuravesta Rastan, Holden T Maecker, Hannes L Röst, Michael P Snyder, Ronald W Davis
INTRODUCTION: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) presents substantial challenges in patient care due to its intricate multisystem nature, comorbidities, and global prevalence. The heterogeneity among patient populations, coupled with the absence of FDA-approved diagnostics and therapeutics, further complicates research into disease etiology and patient managment. Integrating longitudinal multi-omics data with clinical, health,textual, pharmaceutical, and nutraceutical data offers a promising avenue to address these complexities, aiding in the identification of underlying causes and providing insights into effective therapeutics and diagnostic strategies...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38650866/the-role-of-the-nucleus-basalis-of-meynert-in-neuromodulation-therapy-a-systematic-review-from-the-perspective-of-neural-network-oscillations
#30
REVIEW
Liwu Jiao, Huicong Kang, Yumei Geng, Xuyang Liu, Mengying Wang, Kai Shu
As a crucial component of the cerebral cholinergic system and the Papez circuit in the basal forebrain, dysfunction of the nucleus basalis of Meynert (NBM) is associated with various neurodegenerative disorders. However, no drugs, including existing cholinesterase inhibitors, have been shown to reverse this dysfunction. Due to advancements in neuromodulation technology, researchers are exploring the use of deep brain stimulation (DBS) therapy targeting the NBM (NBM-DBS) to treat mental and neurological disorders as well as the related mechanisms...
2024: Frontiers in Aging Neuroscience
https://read.qxmd.com/read/38650815/green-synthesis-of-molybdenum-nanoparticles-from-solanum-xanthocarpum-and-evaluation-of-their-antimicrobial-and-antioxidant-activity-against-multidrug-resistant-wound-isolates
#31
JOURNAL ARTICLE
Priyam Bharathidasan, Muthuvel Surya, P Geetha Sravanthy, Muthupandian Saravanan
INTRODUCTION: In recent years, antimicrobial drug resistance has emerged as a serious global public health concern, according to the World Health Organization data. The emergence of pathogens resistant to multiple drugs has been linked to an increase in morbidity and mortality from microbial infections. The study's main goal is to explore the efficacy of using Solanum xanthocarpum in the green synthesis of molybdenum nanoparticles (Mo NPs) for antibacterial and antioxidant properties...
March 2024: Curēus
https://read.qxmd.com/read/38650755/clinical-characteristics-and-analysis-of-associated-risk-factors-in-patients-with-severe-and-non-severe-covid-19-infection
#32
JOURNAL ARTICLE
Yong Zhou, Zhen Wang, Fei Chen, Ying-Xia Xiong, Wei Wang, Jun-Min Huang, Wei Fang
OBJECTIVE: Our aim was to highlight the clinical characteristics and determine the risk factors associated with severe and non-severe COVID-19 infection. STUDY METHOD: A retrospective review was conducted on clinical data obtained from patients with COVID-19 infection, admitted to the emergency department between November 2022 and January 2023. Total of 1684 participants were categorized into severe (312 cases,18.53%) and non-severe (1,372 cases,81.47%) cohorts...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38650753/predicting-antibiotic-tolerance-in-hvkp-and-ckp-respiratory-infections-through-biofilm-formation-analysis-and-its-resistance-implications
#33
JOURNAL ARTICLE
Zhongwei Wen, Yiqiang Chen, Tangjuan Liu, Jiahui Han, Yuting Jiang, Ke Zhang
INTRODUCTION: Respiratory infections are a major global health concern, with Klebsiella pneumoniae standing out due to its evolving antibiotic resistance. This study compares the resistance profiles of hypervirulent Klebsiella pneumoniae (hvKP) and classical Klebsiella pneumoniae (cKP), aiming to shed light on their clinical implications. METHODS: We analyzed 86 cases, comprising 42 hvKP and 44 cKP strains, using comprehensive antimicrobial susceptibility testing and clinical data evaluation to assess antibiotic tolerance and resistance mechanisms...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38650714/exploration-of-factors-affecting-hemodynamic-stability-following-pheochromocytoma-resection-cohort-study
#34
JOURNAL ARTICLE
Lidan Liu, Lihua Shang, Yimeng Zhuang, Xiaojing Su, Xue Li, Yumeng Sun, Bo Long
PURPOSE: Surgery is the only way to cure pheochromocytoma; however, postoperative hemodynamic instability is one of the main causes of serious complications and even death. This study's findings provide some guidance for improved clinical management. PATIENTS AND METHODS: This study was to investigate the factors leading to postoperative hemodynamic instability in the postoperative pathology indicated pheochromocytoma from May 2016 to May 2022. They were divided into two groups according to whether vasoactive drugs were used for a median number of days or more postoperatively...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38650712/anlotinib-for-metastatic-progressed-pheochromocytoma-and-paraganglioma-a-retrospective-study-of-real-world-data
#35
JOURNAL ARTICLE
Rui Tian, Xiaochen Yao, Jieping Song, Jun Wang, Jingjing Fu, Liang Shi, Fei Yu, Pengjun Zhang, Chuan Zhang, Yudan Ni, Feng Wang
INTRODUCTION: Pheochromocytomas (PCC) and paragangliomas (PGL) (collectively PPGL) are a type of rare hypervascular neuroendocrine tumors that are very challenging to treat. This study aimed to determine the efficacy and safety of the multi-tyrosine kinase inhibitor anlotinib for the treatment of locally advanced or metastatic (LA/M) PPGL. METHODS: A total of 37 eligible patients with unresectable or progressive LA/M PPGL were enrolled. Of them, 27 patients received anlotinib alone (n = 19) or in combination (n = 8) with radionuclide therapies, including peptide receptor radionuclide therapy (PRRT) and iodine 131 meta-iodobenzylguanidine (131 I-MIBG)...
April 6, 2024: Journal of the Endocrine Society
https://read.qxmd.com/read/38650627/sishen-pill-and-its-active-phytochemicals-in-treating-inflammatory-bowel-disease-and-colon-cancer-an-overview
#36
REVIEW
Boxun Zhang, Yingying Cheng, Qin Jian, Sirui Xiang, Qi Xu, Chuchu Wang, Chuan Yang, Junzhi Lin, Chuan Zheng
The incidence of inflammatory bowel disease (IBD) and the associated risk of colon cancer are increasing globally. Traditional Chinese medicine (TCM) treatment has unique advantages. The Sishen Pill, a common Chinese patented drug used to treat abdominal pain and diarrhea, consists mainly of Psoraleae Fructus, Myristicae Semen, Euodiae Fructus, and Schisandra Chinensis. Modern research has confirmed that Sishen Pill and its active secondary metabolites, such as psoralen, myristicin, evodiamine, and schisandrin, can improve intestinal inflammation and exert antitumor pharmacological effects...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38650418/-nephroprotective-value-of-n-acetylcysteine-for-patients-with-concomitant-trauma-as-well-as-other-aspects-of-the-use-of-this-drug-in-clinical-practice
#37
JOURNAL ARTICLE
A Miziev I, Kh Makhov M, B Makhova A, A Shiritova L, B Gubzhokova L
An analysis and review of domestic and foreign literature on the role of N-acetylcysteine in the correction of oxidative stress, as well as the problem of oxidative stress, and protection against free radicals are presented in the article. The important role of N-acetylcysteine in replenishing the intracellular glutathione level, which is the main cell antioxidant, has been shown, as well as the potential use of N-acetylcysteine for various pathological conditions and diseases. The relevance of concomitant injury and renal dysfunction, and the experience of the clinical use of N-acetylcysteine as a nephroprotector in patients with concomitant injury in the clinic of the Department of Faculty and Endoscopic Surgery of KBSU named after Kh...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38650408/-practical-use-of-adenoprosin-in-combination-therapy-in-men-with-lower-urinary-tract-symptoms
#38
JOURNAL ARTICLE
R Kasyan G, A Khodyreva L, L Grigoryan B, V Dyakov V
AIM: The aim of the observational cohort study is to study and evaluate the efficiency of the drug Adenoprosin in combination with other drugs in comparison with monotherapy. MATERIALS AND METHODS: Data from 6,442 patients at 221 medical institutions in 39 cities from November 2020 to December 2022 were analyzed. The drug Adenoprosin in the form of rectal suppositories was prescribed as monotherapy in group I, while patients in group II received Adenoprosin in a combination with other drugs...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38650399/-outpatient-treatment-and-quality-of-life-of-patients-with-interstitial-cystitis-and-hunners-lesion-cohort-cross-sectional-study
#39
JOURNAL ARTICLE
E Karasev A, I Bresso T, D Markova O, R Kasyan G, Yu Pushkar D
AIM: To assess the quality of life of patients with interstitial cystitis (IC) and to study effective options used to control symptoms on outpatient basis. MATERIALS AND METHODS: The results of a descriptive prospective cross-sectional cohort study are presented. The medical charts of patients who were treated in the City Clinical Hospital named after Spasokukotsky from 2021 to 2023 were analyzed. Eighty inpatient medical charts of various patients with a final diagnosis of IC with Hunner's lesion were identified...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38650383/current-strategies-for-targeting-hpk1-in-cancer-and-the-barriers-to-preclinical-progress
#40
JOURNAL ARTICLE
Hui Chen, Xiangna Guan, Chi He, Tingting Lu, Xingyu Lin, Xuebin Liao
INTRODUCTION: Hematopoietic progenitor kinase 1 (HPK1), a 97-kDa serine/threonine Ste20-related protein kinase, functions as an intracellular negative regulator, primarily in hematopoietic lineage cells, where it regulates T cells, B cells, dendritic cells and other immune cells. Loss of HPK1 kinase activity results in exacerbated cytokine secretion, enhanced T cell signaling, improved viral clearance, and thus increased restraint of tumor growth. These findings highlight HPK1 as a promising target for immuno-oncology treatments, culminating in the advancement of candidate compounds targeting HPK1 to clinical trials by several biotech enterprises...
April 22, 2024: Expert Opinion on Therapeutic Targets
keyword
keyword
112435
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.